MedPath

Saffron in the treatment of postmenopausal hot flash

Phase 3
Completed
Conditions
Hot flashing.
Menopausal and female climacteric states
Registration Number
IRCT201602031556N85
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
50
Inclusion Criteria

women aged between 45-65 years old; menopause.
Exclusion criteria: moderate to severe post-menopausal hot flushing-five episodes per day from 2 months ago; sopping of the mens from 12 month ago; receiving estrogen or progesterone during the last two months; receiving antidepressants during the last month; receving Selective Estrogen Receptor Modulators including raloxifen and tamoxifen during the last month; receiving aromatase inhibitors such as Anastrozole, Letrozole, Exemestane during the last month;receving Leuprolide acetate during the last month; receiving clonidine during the last month; receving gabapentine and pregabalin during the last month; receiving hot flushing reducing medications during the last month; receiving amino acid supplements during the last month.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.